ADC Therapeutics SA (ADCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has a cash flow conversion efficiency ratio of 0.137x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.71 Million) by net assets ($-216.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ADC Therapeutics SA defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
ADC Therapeutics SA - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how ADC Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ADC Therapeutics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADC Therapeutics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KJTS
KLSE:0293
|
0.018x |
|
EUROZ Hartleys Group Ltd
AU:EZL
|
0.132x |
|
LEWAG Holding Aktiengesellschaft
F:KGR
|
-0.084x |
|
BANK OF JIUJIANG H YC1
F:BJ8
|
N/A |
|
Sunko Ink Co Ltd
TW:1721
|
0.009x |
|
Asian Hotels (North) Limited
NSE:ASIANHOTNR
|
-0.675x |
|
Buligo Capital Ltd
TA:BLGO
|
0.026x |
|
Muhak Co. Ltd
KO:033920
|
-0.009x |
Annual Cash Flow Conversion Efficiency for ADC Therapeutics SA (2017–2025)
The table below shows the annual cash flow conversion efficiency of ADC Therapeutics SA from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of ADC Therapeutics SA.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-185.83 Million | $-141.17 Million | 0.760x | +24.31% |
| 2024-12-31 | $-202.64 Million | $-123.83 Million | 0.611x | -23.67% |
| 2023-12-31 | $-148.25 Million | $-118.69 Million | 0.801x | +145.99% |
| 2022-12-31 | $79.45 Million | $-138.31 Million | -1.741x | -23.89% |
| 2021-12-31 | $166.09 Million | $-233.38 Million | -1.405x | -179.40% |
| 2020-12-31 | $335.50 Million | $-168.73 Million | -0.503x | +54.02% |
| 2019-12-31 | $111.16 Million | $-121.58 Million | -1.094x | -13.78% |
| 2018-12-31 | $126.24 Million | $-121.36 Million | -0.961x | -219.61% |
| 2017-12-31 | $249.17 Million | $-74.94 Million | -0.301x | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more